Key result
Empagliflozin plus standard of care was cost-effective for HFrEF patients in Japan, yielding an incremental cost-effectiveness ratio of ¥469,672/QALY ($3,608/QALY).
Why the study?
The economic implications of sodium-glucose co-transporter 2 inhibitors in patients with heart failure have not been sufficiently elucidated in Japan.
Does empagliflozin plus standard of care improve cost-effectiveness compared to standard of care alone in patients with HFrEF in Japan?
Does empagliflozin plus standard of care improve cost-effectiveness compared to standard of care alone in patients with HFrEF in Japan?
Effect estimate: ICER ¥469,672/QALY ($3,608/QALY)
Empagliflozin added to standard of care is highly cost-effective for patients with HFrEF in Japan, driven by reduced heart failure hospitalization costs.
Supports the economic viability of adding empagliflozin for HFrEF in.
BACKGROUND: Several studies have reported the cost-effectiveness of sodium-glucose co-transporter 2 inhibitors in heart failure patients; however, their economic implications have not been sufficiently elucidated in Japan. METHODS: A Markov cohort model was developed to evaluate the cost-effectiveness of empagliflozin plus standard of care (SoC) vs. SoC for patients with heart failure with reduced ejection fraction (HFrEF) in Japan. Model inputs, including risk of clinical events, costs, and utilities based on Kansas City Cardiomyopathy Questionnaire Clinical Summary Scores were derived from EMPEROR-Reduced trial data, published literature, and a claims database. RESULTS: The model predicted lower lifetime hospitalizations for heart failure (HHFs) and additional quality-adjusted life-years (QALYs; 0.21) for empagliflozin plus SoC vs. SoC in the overall population. Increased costs of ¥100,495/patient ($772/patient), primarily driven by higher drug costs of ¥239,558/patient ($1,840/patient), were largely offset by reduced HHF management costs of -¥166,160/patient (-$1,276/patient), yielding an incremental cost-effectiveness ratio (ICER) of ¥469,672/QALY ($3,608/QALY). Results were consistent among subgroups and sensitivity analyses. In probabilistic sensitivity analysis, 82.5 % of runs were below the Japanese ICER reference value of ¥5,000,000/QALY ($38,408/QALY). CONCLUSIONS: Empagliflozin was demonstrated to be cost-effective for HFrEF patients in Japan based on the EMPEROR-Reduced trial data.
No takes yet. Share an insight, caveat, or question.
Tsutsui et al. (2023) studied heart failure with reduced ejection fraction (HFrEF). Empagliflozin vs. Standard of care (SoC) was evaluated on Incremental cost-effectiveness ratio (ICER) (ICER ¥469,672/QALY ($3,608/QALY)). Empagliflozin plus standard of care was cost-effective for HFrEF patients in Japan, yielding an incremental cost-effectiveness ratio of ¥469,672/QALY ($3,608/QALY).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: